Log in to your Inderes Free account to see all free content on this page.
Xintela
0.23 SEK
-5.39 %
Less than 1K followers
XINT
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Xintela
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 0.0 | 0.1 | 4.2 | 2.3 | |||
| growth-% | 5,175.0 % | -45.9 % | |||||
| EBITDA | -38.0 | -30.3 | -40.1 | -69.1 | -57.2 | -39.5 | -46.1 |
| EBIT | -38.0 | -33.9 | -43.6 | -69.1 | -57.2 | -39.5 | -46.7 |
| Profit before taxes | -38.1 | -50.3 | -44.1 | -73.2 | -58.4 | -41.5 | -50.2 |
| Net income | -43.5 | -50.3 | -58.4 | -66.2 | -54.1 | -39.2 | -48.6 |
| EPS | -0.61 | -0.40 | -0.38 | -0.37 | -0.13 | -0.07 | -0.07 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Login required
This content is only available for logged in users
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -100,123.7 % | -71,550.0 % | -934.8 % | -2,019.2 % | |||
| EBIT-% | -100,123.7 % | -71,550.0 % | -934.8 % | -2,045.7 % | |||
| ROE | -466.9 % | -182.0 % | -1,479.5 % | -1,145.7 % | -1,234.7 % | 658.7 % | 921.0 % |
| ROI | -254.7 % | -103.6 % | -236.0 % | -270.1 % | -293.9 % | -158.0 % | -167.3 % |
Login required
This content is only available for logged in users